Compare Ascendis Pharma A/S (ASND) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Warner Music Group Corp — how do they compare? Ascendis Pharma A/S trades at $256.21 (market cap $16.67B), while Warner Music Group Corp trades at $24.65 (market cap $13.12B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Warner Music Group Corp pays a 3.19% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WMG | |
|---|---|---|
Market Cap | $16.67B | $13.12B |
Sector | Health | Media |
52-Week High | $277.18 | $34.72 |
52-Week Low | $189.74 | $23.65 |
Enterprise Value | $17.04B | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Warner Music Group (WMG) trades at $26.41, up 0.08% on the day, with a bearish technical signal but improving fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $7.3B projected for 2026. The stock shows a P/E of 20.06 and net income margin of 9.2%, supported by strong cash flow and dividend payments. Key resistance is at $27, with support at $26.
WMG presents a mixed outlook: bullish fundamentals with earnings beats and growth, but technicals indicate near-term pressure. Opportunities include streaming expansion and AI integration, while risks involve leadership changes and market volatility. Analyst consensus is 66.7% buy, suggesting long-term value if technical resistance is overcome.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
